Effects of glucocorticoids on weight change during the treatment of Wegener's granulomatosis
dc.contributor.author | Wung, Peter K. | en_US |
dc.contributor.author | Anderson, Troy | en_US |
dc.contributor.author | Fontaine, Kevin R. | en_US |
dc.contributor.author | Hoffman, Gary S. | en_US |
dc.contributor.author | Specks, Ulrich | en_US |
dc.contributor.author | Merkel, Peter A. | en_US |
dc.contributor.author | Spiera, Robert F. | en_US |
dc.contributor.author | Davis, John C. | en_US |
dc.contributor.author | St. Clair, E. William | en_US |
dc.contributor.author | McCune, William Joseph | en_US |
dc.contributor.author | Stone, John H. | en_US |
dc.date.accessioned | 2008-06-04T14:36:16Z | |
dc.date.available | 2009-06-01T20:08:52Z | en_US |
dc.date.issued | 2008-05-15 | en_US |
dc.identifier.citation | Wung, Peter K.; Anderson, Troy; Fontaine, Kevin R.; Hoffman, Gary S.; Specks, Ulrich; Merkel, Peter A.; Spiera, Robert; Davis, John C.; St.Clair, E. William; McCune, W. Joseph; Stone, John H. (2008). "Effects of glucocorticoids on weight change during the treatment of Wegener's granulomatosis." Arthritis & Rheumatism 59(5): 746-753. <http://hdl.handle.net/2027.42/58632> | en_US |
dc.identifier.issn | 0004-3591 | en_US |
dc.identifier.issn | 1529-0131 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/58632 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=18438908&dopt=citation | en_US |
dc.description.abstract | Objective Weight gain is a side effect of glucocorticoid (GC) use, but the natural history and health implications of changes in weight that occur during the treatment of inflammatory disease are not understood. Methods We evaluated data from the Wegener's Granulomatosis Etanercept Trial. Patients were categorized according to clinical outcome at 1 year: remission (no disease flares), single flare, or multiple flares. Risk factors for gaining ≥10 kg were examined in multivariate models. Results Weights at baseline and 1 year were available for 157 (93%) of the 168 patients analyzed. During year 1, the mean cumulative prednisone dosage in the multiple flares subgroup was 7.9 gm, compared with 6.0 gm and 3.9 gm in the single flare and remission subgroups, respectively ( P < 0.001). Patients in these subgroups gained an average of 2.6 kg, 4.1 kg, and 5.8 kg, respectively ( P = 0.005). Weight gain did not correlate with cumulative GC dose (R = 0.10, P = 0.25). Thirty-five patients (22.3%) gained and maintained ≥10 kg in the first year. New diagnosis of Wegener's granulomatosis at baseline was an independent predictor of gaining ≥10 kg at 1 year (odds ratio 19.7, 95% confidence interval 2.4–162.6, P = 0.006). Among the 78 patients in the remission subgroup, 40 sustained remissions through the 2-year time point. For these 40 patients, the mean weight gained at year 1 did not regress by the end of year 2, despite the absence of continued GC use. Conclusion Disease control was associated with lower cumulative GC doses but greater weight gain. More than one-fifth of patients gained >10 kg in the first year of treatment. The quantity of weight gained by patients during treatment has potential future health implications. | en_US |
dc.format.extent | 290087 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.title | Effects of glucocorticoids on weight change during the treatment of Wegener's granulomatosis | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Geriatrics | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | University of Michigan, Ann Arbor | en_US |
dc.contributor.affiliationother | Johns Hopkins University School of Medicine, Baltimore, Maryland ; Dr. Wung and Mr. Anderson contributed equally to this work. | en_US |
dc.contributor.affiliationother | Johns Hopkins University School of Medicine, Baltimore, Maryland | en_US |
dc.contributor.affiliationother | Johns Hopkins University School of Medicine, Baltimore, Maryland | en_US |
dc.contributor.affiliationother | Cleveland Clinic Foundation, Cleveland, Ohio | en_US |
dc.contributor.affiliationother | Mayo Clinic, Rochester, Minnesota | en_US |
dc.contributor.affiliationother | Boston University School of Medicine, Boston, Massachusetts | en_US |
dc.contributor.affiliationother | Beth Israel Medical Center, New York, New York | en_US |
dc.contributor.affiliationother | University of California at San Francisco | en_US |
dc.contributor.affiliationother | Duke University Medical Center, Durham, North Carolina ; Dr. St.Clair received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Genentech, Medimmune, Human Genome Sciences, Novartis, and Bristol-Meyers Squibb. | en_US |
dc.contributor.affiliationother | Johns Hopkins University School of Medicine, Baltimore, Maryland ; Rheumatic Diseases Unit, Massachusetts General Hospital, 55 Fruit Street, Yawkey Center 2C, Boston, MA 02114 | en_US |
dc.identifier.pmid | 18438908 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/58632/1/23561_ftp.pdf | |
dc.identifier.doi | http://dx.doi.org/10.1002/art.23561 | en_US |
dc.identifier.source | Arthritis & Rheumatism | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.